People who inherit a BRCA2 mutation have a 70 per cent lifetime risk of breast cancer. Therapeutic targets to prevent cancer from happening in these at-risk patients remain a significant unmet need.
This session will explore the comprehensive profiling of patient samples with BRCA2 mutations, and a preclinical model, to identify aberrant luminal progenitors as likely breast cancer cells-of-origin.
This will include presenting preclinical data establishing a biological rationale for chemoprevention (the use of a therapeutic to prevent cancer occuring) for carriers of the BRCA2 mutation.
Dr Joyce is a Peeneeyt Thanampool Indigenous Postdoctoral Research Fellow at the University of Melbourne and WEHI. Dr Joyce is an early career stem cell/cancer cell biologist focused on revealing novel targets for cancer prevention in at-risk populations. Their PhD work on novel chemoprevention strategies for BRCA mutation carriers was completed under the supervision of Professor Jane Visvader and Professor Geoffrey Lindeman at WEHI.
